Invyncible review

What it is

Invyncible is a telehealth brand operating as Nationwide Telemedicine, LLC from 204 37th Ave N., #337, St. Petersburg, Florida, with a published phone number and a LegitScript verification seal in the footer. Its treatments page lists a full catalogue with prices: compounded semaglutide and tirzepatide in several formulations, brand-name Zepbound and Wegovy, Sermorelin 9 mg at $179.10, NAD+ Injections at $192, Glutathione Injections at $88, Lipo (MIC+B12) at $108, B12 at $90 and low-dose naltrexone at $60. It is explicit about what it is not: its own copy states it provides telemedicine consultations, offers structured programs and coordinates with licensed pharmacies, and that it does not compound, dispense or sell medications.

How it works

Telemedicine consultation, structured program, and coordination with an independent licensed pharmacy — with the role boundary stated by the company itself rather than left for you to infer. That self-description is worth reading twice, because it tells you where responsibility sits: Invyncible is the front end, and someone else, unnamed, makes and ships the product. State coverage is published as an exclusion list on every product page rather than an inclusion list, which is an unusual and actually rather honest format — you can check your own state in one line. As of this review, the notice reads that products are not available in Alabama, Arkansas, California, Hawaii, Kansas, Massachusetts, Michigan, Minnesota or Oregon, which puts availability at 41 states; our earlier record captured Mississippi in that list too, so the exclusions have narrowed by one. There is no long-term commitment and no early-termination fee, though the refund policy is not stated. What is missing throughout is people and provenance: no compounding pharmacy is named, no 503A or 503B designation is given, and no medical director or clinical leadership is listed anywhere.

Pricing transparency

The most completely published menu in this batch, and the one that most needs its own footnote. Sermorelin 9 mg is listed at $179.10, NAD⁺ injections at $192 and glutathione injections at $88, all visible without an intake. But Invyncible states directly that its programs are sold as a vial with an approximate duration based on a weekly injection cycle — the tirzepatide page, for instance, reads "Program 1: ~2.25 mg weekly / 9 mg vial → ~4 weeks" — so a published figure represents roughly four to five weeks of supply rather than a monthly subscription rate. That is why we do not carry any of these numbers as a monthly floor, and why comparing $179.10 against a competitor's $199-a-month is not a like-for-like comparison until you know how long the 9 mg sermorelin vial is meant to last at your dose. Ask for that explicitly. Ask too whether shipping is charged — the site says refrigerated products must ship overnight but states no shipping cost — and what the refund position is, since none is published.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Invyncible states that it does not compound or dispense, and coordinates with licensed pharmacies, but names none of them and gives no 503A or 503B designation — compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, so an unnamed compounder is a substantive gap rather than a paperwork one. There is also a catalogue error worth knowing about before you rely on any product description here: its Wegovy card describes the product as the FDA-approved brand-name tirzepatide treatment. Wegovy is semaglutide; tirzepatide is a different molecule with a different receptor profile. That is a drug-class error on a product page, and it is a reason to verify the active ingredient of anything you order rather than trusting the card. On the evidence, the three wellness products are not equivalent. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, but the long-term human outcome data stays thin and no controlled trial demonstrates the body-composition or recovery results it is marketed for. Injected NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and raise blood NAD⁺, a biomarker rather than a benefit. Injectable glutathione has essentially no controlled human outcome evidence at all. Individual results vary.

Pros and watch-outs

The evidence behind what Invyncible prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Invyncible compares

A few alternatives worth a look, depending on what you’re optimizing for.

• CoreAge Rx

  Injected or intranasal NAD⁺ at a published price across 50 states

  See CoreAge Rx →
• SLSystem Labs

  NAD⁺ bundled with glutathione, B-12 and sermorelin from one service

  See System Labs →
• Invigor Medical

  Prescription at-home NAD⁺ injections via telehealth

  See Invigor Medical →